Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

SPLS delivers comparable safety outcomes on obese, nonobese colorectal cancer patients

23 Aug 2017

There is no apparent difference in safety outcomes of single-port laparoscopic surgery (SPLS) between obese and nonobese colorectal cancer patients, a new retrospective cohort study has found.

“Hence, SPLS can be safely recommended for colorectal cancer in obese patients if the surgeon is experienced. Nevertheless, the technique used warrants further investigation, and a large-scale prospective study is required,” researchers said.

The study included 323 colorectal cancer patients who received SPLS. Only those ≥18 years of age and with malignancies in the colon or rectum were included. Exclusion criteria were emergency SPLS and resection of other organs.

Participants were stratified into three according to BMI: nonobese (BMI <25.0 kg/m2; n=2323), obese I (BMI 25.0 to 29.9 kg/m2; n=80) and obese II (BMI ≥30.0 kg/m2; n=10). Outcomes were 30-day reoperation, 30-day mortality and adverse events within 30 days of operation.

The mean operation time in nonobese patients (269.2±110.2 minutes) was not significantly different than in obese I (270.4±81.7 minutes) and obese II (342.8±182.6 minutes; p=0.247) patients. There were also no significant differences in estimated surgical blood loss among the three groups (277.7±208.5 vs 260.5±209.2 vs 387.0±278.3, respectively; p=0.205).

Mortality (p=0.404) and conversion (p=0.937) rates were also comparable in nonobese (0.9 percent for both), obese I (0 and 1.3 percent, respectively) and obese II (0 percent for both) patients.

Time to flatus was significantly different among the three groups (2.2±1.7 vs 2.0±1.8 vs 3.0±1.6 for nonobese, obese I and obese II patients, respectively; p=0.04).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.